Trial Search Results

iTBS in Refractory Pediatric Depression

This work will mark the first step in understanding the neural targets for rTMS in youth with difficult to treat depressive symptoms, creating benchmarks for optimizing the safety and efficacy of rTMS for pediatric populations through precision targeting, and encourage funding applications for larger sham- controlled randomized clinical studies.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Device: Intermittent Theta Burst Stimulation




Inclusion Criteria:

   - 10 participants ages 12-21 years of age

   - with at least moderate to severe depressive symptoms confirmed by the Children's
   Depression Rating Scale-Revised (CDRS-R>40) or Hamilton Rating Scale for Depression
   (HRSD-17 ≥ 18)

   - able to commit to protocol schedule and provide Informed consent by a legal guardian
   and assent by a youth participant

   - have had at least one prior antidepressant treatment failure with adequate dose and

Exclusion Criteria:

   - prior neurological diagnosis (neurodevelopmental disorders, strokes/traumatic brain
   injuries, brain tumor, epilepsy)

   - contraindications for TMS or MRI e.g. have any implanted metal

   - unstable medical conditions

   - acute suicide risk, defined as an attempt in past 6 months that required medical
   treatment, or history of ≥2 suicide attempts in the past 12 months, or has a clear cut
   plan for suicide

   - pregnancy, suspected pregnancy or not on birth control if sexually active; 6)
   Inability to locate and quantify a motor threshold

   - any factor that the PI determines to be reason for exclusion.

Ages Eligible for Study

12 Years - 21 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Romina Nejad, BS